NetworkNewsBreaks — Longeveron Inc. (NASDAQ: LGV
Post# of 50
(Total Views: 144)
Posted On: 12/20/2023 3:51:27 PM
NetworkNewsBreaks — Longeveron Inc. (NASDAQ: LGVN) Reports Additional Positive Clinical Data, Imaging Biomarker Results in Phase 2a Lomecel-B(TM) Trial
Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (HLHS), Alzheimer’s disease and Aging-Related Frailty, is releasing new clinical and biomarker results from the CLEAR MIND trial of its investigational product Lomecel-B(TM). The phase 2a trial evaluates Lomecel-B for the treatment of mild Alzheimer’s disease. According to the report, the new data indicates that that Lomecel-B improved cognitive function in multiple measures in a dose-response fashion. In addition, caregiver ratings showed improved quality of life in patients receiving Lomecel-B, and MRI Biomarker study data indicates that Lomecel-B countered loss of brain volume in multiple areas associated with Alzheimer’s disease while also reducing brain neuroinflammation and improving cerebral blood flow. The CLEAR MIND trial is a randomized, double-blinded, placebo-controlled study comprised of 50 patients, ages 60 to 85 years of age and diagnosed with mild Alzheimer’s disease. “These new data support our initial results for CLEAR MIND that we announced in October and provide further validation of both the safety and therapeutic potential of Lomecel-B in the treatment of mild Alzheimer’s disease,” said Longeveron CEO Wa’el Hashad in the press release. “We believe these new data may provide evidence for Lomecel-B’s mechanism of action and add to the robust foundation we are building for its further investigation in Alzheimer’s disease as well as other indications. We anticipate presenting the CLEAR MIND results in a major medical meeting in 2024.”
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (HLHS), Alzheimer’s disease and Aging-Related Frailty, is releasing new clinical and biomarker results from the CLEAR MIND trial of its investigational product Lomecel-B(TM). The phase 2a trial evaluates Lomecel-B for the treatment of mild Alzheimer’s disease. According to the report, the new data indicates that that Lomecel-B improved cognitive function in multiple measures in a dose-response fashion. In addition, caregiver ratings showed improved quality of life in patients receiving Lomecel-B, and MRI Biomarker study data indicates that Lomecel-B countered loss of brain volume in multiple areas associated with Alzheimer’s disease while also reducing brain neuroinflammation and improving cerebral blood flow. The CLEAR MIND trial is a randomized, double-blinded, placebo-controlled study comprised of 50 patients, ages 60 to 85 years of age and diagnosed with mild Alzheimer’s disease. “These new data support our initial results for CLEAR MIND that we announced in October and provide further validation of both the safety and therapeutic potential of Lomecel-B in the treatment of mild Alzheimer’s disease,” said Longeveron CEO Wa’el Hashad in the press release. “We believe these new data may provide evidence for Lomecel-B’s mechanism of action and add to the robust foundation we are building for its further investigation in Alzheimer’s disease as well as other indications. We anticipate presenting the CLEAR MIND results in a major medical meeting in 2024.”
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Longeveron Inc. (LGVN) Stock Research Links
Scroll down for more posts ▼